Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

Hunan Province Tumor Hospital

Status and phase

Not yet enrolling

Phase 2

Conditions

Non-small Cell Lung Cancer

Treatments

Drug: third-generation EGFR-TKI combined with anlotinib

Study type

Interventional

Funder types

Other

Identifiers

NCT06634667

20241006

Details and patient eligibility

About

This study aimed to evaluate the efficacy and safety of third-generation EGFR-TKI plus anlotinib as maintenance after chemotherapy plus immunotherapy in advanced NSCLC with small cell transformation after EGFR-TKI resistance.

Full description

This prospective interventional clinical study aims to evaluate the efficacy and safety of third-generation EGFR-TKI combined with anlotinib as maintenance therapy following 4-6 cycles of chemotherapy and immunotherapy in patients with advanced NSCLC who developed small cell transformation after EGFR-TKI resistance.Approximately 30 non-small cell lung cancer patients who developed small cell transformation after EGFR-TKI resistance were enrolled and treated with 4-6 cycles of chemotherapy plus immunotherapy followed by maintenance therapy with third-generation EGFR-TKI combined with anlotinib.The study is expected to commence recruitment in mainland China in about November 2024. It is expected that the trial will end in December 2026.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
1. Age ≥ 18 years.
1. Histopathology is confirmed non-small cell lung cancer .
4.Patients with advanced non-small cell lung cancer (NSCLC) who experienced small cell transformation after EGFR-TKI resistance.
1. Predicted survival ≥ 12 weeks. .
1. ECOG 0-2.
1. Adequate bone marrow hematopoiesis and organ function.

Exclusion criteria

1. History of other malignant tumors within 2 years.
1. Adverse events (except alopecia of any degree) of CTCAE > grade 1 due to prior treatment (e.g., adjuvant chemotherapy, radiotherapy, etc.) prior to the first dose.
1. History of stroke or intracranial hemorrhage within 6 months prior to the first dose.
1. The presence of any severe or poorly controlled systemic disease, including poorly controlled hypertension and active bleeding in the judgment of the investigator.
1. Subjects with persistent or active infection, including but not limited to hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) and COVID-19 infection.
1. Heart-related diseases or abnormalities
1. Past history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or interstitial lung disease with active clinical symptoms, immune pneumonia caused by immunotherapy.
1. Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing drugs, or inability to adequately absorb sunvozertinib or anlotinib due to previous bowel resection.
1. Live vaccine was given 2 weeks before the first medication.
1. Women who are breastfeeding or pregnant.
1. Hypersensitivity to the test drug and the ingredients.
1. Other conditions assessed by the investigator to be unsuitable for participation in the study.